COGNITION THERAPEUTICS INC financial data

Symbol
CGTX on Nasdaq
Location
Purchase, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 278% % -9.2%
Debt-to-equity 57% % 14%
Return On Equity -150% % 0.54%
Return On Assets -96% % 4.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 88,274,258 shares 112%
Common Stock, Shares, Outstanding 88,268,078 shares 116%
Entity Public Float $56,312,451 USD 31%
Common Stock, Value, Issued $88,000 USD 115%
Weighted Average Number of Shares Outstanding, Basic 77,951,513 shares 93%
Weighted Average Number of Shares Outstanding, Diluted 77,951,513 shares 93%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $34,194,000 USD -24%
General and Administrative Expense $10,657,000 USD -20%
Operating Income (Loss) $44,851,000 USD 23%
Net Income (Loss) Attributable to Parent $27,986,000 USD 18%
Earnings Per Share, Basic 0 USD/shares 52%
Earnings Per Share, Diluted 0 USD/shares 52%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $39,334,000 USD 79%
Assets, Current $42,883,000 USD 60%
Property, Plant and Equipment, Net $159,000 USD -23%
Operating Lease, Right-of-Use Asset $353,000 USD -35%
Assets $43,395,000 USD 57%
Accounts Payable, Current $827,000 USD -56%
Employee-related Liabilities, Current $1,296,000 USD -12%
Accrued Liabilities, Current $3,923,000 USD -59%
Liabilities, Current $6,654,000 USD -48%
Deferred Income Tax Liabilities, Net $110,000 USD -25%
Operating Lease, Liability, Noncurrent $212,000 USD -46%
Other Liabilities, Noncurrent $0 USD
Liabilities $6,866,000 USD -48%
Retained Earnings (Accumulated Deficit) $195,304,000 USD -17%
Stockholders' Equity Attributable to Parent $36,529,000 USD 152%
Liabilities and Equity $43,395,000 USD 57%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $9,877,000 USD -36%
Net Cash Provided by (Used in) Financing Activities $1,296,000 USD -89%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 88,268,078 shares 116%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,581,000 USD -281%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $39,823,000 USD 81%
Deferred Tax Assets, Valuation Allowance $29,400,000 USD 32%
Deferred Tax Assets, Gross $29,510,000 USD 32%
Operating Lease, Liability $380,000 USD -34%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $27,986,000 USD 18%
Lessee, Operating Lease, Liability, to be Paid $424,000 USD -36%
Property, Plant and Equipment, Gross $1,337,000 USD 0.3%
Operating Lease, Liability, Current $168,000 USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year Two $87,000 USD -45%
Lessee, Operating Lease, Liability, to be Paid, Year One $155,000 USD -31%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $44,000 USD -46%
Lessee, Operating Lease, Liability, to be Paid, Year Three $88,000 USD -3.3%
Deferred Tax Assets, Operating Loss Carryforwards $8,491,000 USD 24%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $38,000 USD -59%
Operating Lease, Payments $56,000 USD 0%
Additional Paid in Capital $231,745,000 USD 28%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $27,000 USD 29%
Deferred Tax Assets, Net of Valuation Allowance $110,000 USD -25%
Share-based Payment Arrangement, Expense $2,263,000 USD -47%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%